CoChat

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

Open access
Niesvizky, Ruben, Richardson, Paul G., Rajkumar, S. Vincent, Coleman, Morton, Rosiñol, Laura, Sonneveld, Pieter, Schuster, Michael W., Irwin, David, Stadtmauer, Edward A., Facon, Thierry, Harousseau, Jean‐Luc, Boral, Anthony L., Esseltine, Dixie‐Lee, Anderson, Kenneth C., Bladé, Joan · 2008 · British Journal of Haematology
Cited by 98

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Summary: Quality of response is associated with prolonged overall survival (OS) in newly diagnosed multiple myeloma patients. This cohort study within the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial of bortezomib versus dexamethasone in relapsed myeloma assessed the relationship between quality of response to bortezomib (n = 315) and clinical benefit. Treatment‐free interval (TFI), time to alternative therapy (TTAT), time to progression (TTP) and OS were assessed in response‐evaluable patients in the bortezomib arm in cohorts defined by achievement of complete response (CR; n = 27), very good partial response (VGPR; n = 31), partial response (PR; n = 77), minimal response (MR; n = 21) or non‐response (NR, including stable and progressive disease; n = 159). CR was associated with significantly longer median TFI (24·1 vs. 6·9/6·4 months) and TTAT (27·1 vs. 13·6/14 months) versus VGPR/PR. Median TTP was similar in CR, VGPR and PR cohorts; median OS was not reached. Patients achieving MR appeared to have prolonged median TFI (3·8 vs. 2·3 months), TTAT (8·7 vs. 6·2 months), TTP (4·9 vs. 2·8 months) and OS (24·9 vs. 18·7 months) versus NR. In conclusion, bortezomib had substantial activity in relapsed myeloma patients; CR may be a surrogate marker for significant clinical benefit with bortezomib. MR appeared to be valid as a separate response category in this setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2141.2008.07303.x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 98

Metadata

Authors
Niesvizky, R., Richardson, P. G., Rajkumar, S. V., Coleman, M., Rosiñol, L., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J., Boral, A. L., Esseltine, D., Anderson, K. C., & Bladé, J.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2008-09-05
Volume
143
Issue
1
Pages
46-53
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2076028786
Cited by
98
References
5
FWCI
7.06
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. https://app.cochat.ai/papers/10.1111/j.1365-2141.2008.07303.x
The paper
Niesvizky, R., Richardson, P. G., Rajkumar, S. V., Coleman, M., Rosiñol, L., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J., Boral, A. L., Esseltine, D., Anderson, K. C., & Bladé, J. (2008). The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2008.07303.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.